Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 24:11:7369-7383.
doi: 10.2147/OTT.S177318. eCollection 2018.

The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis

Min Peng  1 , Xing Li  2 , Gu Lei  3 , Yi Ming Weng  1 , Meng Xue Hu  1 , Qi Bin Song  1
Affiliations
Review

The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis

Min Peng et al. Onco Targets Ther. .

Abstract

The value of immune checkpoint inhibitor (ICI) combination therapy for patients with lung cancer remains unclear. We conducted a meta-analysis using PubMed, Embase, and ClinicalTrials.gov databases to identify eligible randomized controlled trials (RCTs) that might provide a reference for clinical practice. The selection criteria were defined according to the population, intervention, comparison, outcome and study design (PICOS) framework. In all, 12 RCTs with 5,989 patients were included in this meta-analysis. Our results showed that ICI combination therapy was significantly associated with the improvement of overall response rate (ORR) (RR =1.44 [95% CI 1.19, 1.74], P=0.0002), progression-free survival (PFS) (HR =0.67 [95% CI 0.59, 0.77], P<0.00001), and OS (HR =0.81 [95% CI 0.70, 0.95], P=0.008) in lung cancer. In subgroup analyses, combination ICI therapy significantly prolonged OS in non-small-cell lung cancer (NSCLC) patients (HR =0.80 [95% CI 0.73, 0.88], P<0.00001) but not in SCLC (HR =0.94 [95% CI 0.82, 1.08], P=0.40) patients. Data suggested that PD-1 inhibitors had higher efficacy and safety profiles than PD-L1 and CTLA-4 inhibitors in combination ICI therapy for lung cancer patients. Furthermore, tolerability analysis revealed higher incidences of grade ≥3 AEs, fatigue, and increased transaminases from combination ICI therapy. In conclusion, our meta-analysis indicated that combination ICI therapy should be considered in clinical practice and future study designs for NSCLC patients. However, the current data do not support the large-scale clinical application of combination ICI therapy in SCLC patients.

Keywords: chemoradiotherapy; combination therapy; immune checkpoint inhibitor; lung cancer; meta-analysis.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow diagram of included and excluded studies.
Figure 2
Figure 2
Meta-analysis of ORR, PFS, and OS. Note: (A) ORR, (B) PFS, and (C) OS. Abbreviations: ORR, overall response rate; PFS, progression-free survival.
Figure 3
Figure 3
Subgroup analysis of ORR. Note: (A) Based on the tumor type, (B) based on the combination type, and (C) based on the ICI type. Abbreviations: ICI, immune checkpoint inhibitor; ORR, overall response rate.
Figure 3
Figure 3
Subgroup analysis of ORR. Note: (A) Based on the tumor type, (B) based on the combination type, and (C) based on the ICI type. Abbreviations: ICI, immune checkpoint inhibitor; ORR, overall response rate.
Figure 4
Figure 4
Subgroup analysis of PFS. Note: (A) Based on the tumor type, (B) based on the combination type, and (C) based on the ICI type. Abbreviations: ICI, immune checkpoint inhibitor; PFS, progression-free survival.
Figure 4
Figure 4
Subgroup analysis of PFS. Note: (A) Based on the tumor type, (B) based on the combination type, and (C) based on the ICI type. Abbreviations: ICI, immune checkpoint inhibitor; PFS, progression-free survival.
Figure 5
Figure 5
Subgroup analysis of OS. Note: (A) Based on the tumor type, (B) based on the combination type, and (C) based on the ICI type. Abbreviation: ICI, immune checkpoint inhibitor.
Figure 5
Figure 5
Subgroup analysis of OS. Note: (A) Based on the tumor type, (B) based on the combination type, and (C) based on the ICI type. Abbreviation: ICI, immune checkpoint inhibitor.
Figure 6
Figure 6
Meta-analysis of grade ≥3 AEs. Abbreviation: AEs, adverse events.
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. - PubMed
    1. Toschi L, Rossi S, Finocchiaro G, Santoro A. Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. Ecancermedicalscience. 2017;11(11):787. - PMC - PubMed
    1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. - PubMed
    1. Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–581. - PMC - PubMed
    1. Pardoll DM. The blockade of immune checkpoints in cancer immuno-therapy. Nat Rev Cancer. 2012;12(4):252–264. - PMC - PubMed